sunitinib

sunitinib2016-11-15T14:43:35+00:00

sunitinib 

CARDIOLOGY, ONCOLOGY, THERAPEUTICS

A receptor tyrosine kinase inhibitor used to manage renal cell carcinoma, pancreatic neuroendocrine tumours, imatinib-resistant GISTs–gastrointestinal stromal tumours, which may be beneficial in managing other malignancies.

Adverse effects Weakness, nausea, vomiting, diarrhoea, constipation, heartburn, bloating, potentially fatal hepatotoxicity; cardiotoxicity (heart failure, myocardial disorders, and cardiomyopathy) is attributed to pericyte damage due to defects in signalling by platelet-derived growth factor receptor, which may be reversed by thalidomide.

Other names SU11248, Sutent

References Sci Transl Med 2013; 5[187]:187ra69

http://www.cancer.gov/cancertopics/druginfo/fda-sunitinib-malate

Leave A Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.